SEC Tracker
Get the app
USNA · XBRL financial data

Usana Health Sciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (USNA's year ends in early January)

In thousands of dollarsSep 30, 2023Dec 30, 2023Mar 30, 2024Jun 29, 2024Sep 28, 2024Dec 28, 2024Mar 29, 2025Jun 28, 2025Sep 27, 2025Jan 3, 2026Apr 4, 2026Jul 4, 2026
Revenue from contracts with customers213,365221,083*227,800212,869200,221213,613*249,539235,848213,670226,200*250,218223,273
Cost of goods and services sold42,52942,319*43,06940,33339,25738,553*52,44550,18448,81549,408*59,43648,339
Gross profit170,836178,764*184,731172,536160,964175,060*197,094185,664164,855176,792*190,782174,934
Research and development—year only———year only———year only——
Selling, general and administrative63,30358,664*64,30064,32561,29573,348*91,43881,90685,94778,081*88,25482,318
Total operating expenses153,229154,545*160,058154,696145,363166,850*181,423168,946163,631172,973*176,908194,930
Operating income (loss)17,60724,219*24,67317,84015,6018,210*15,67116,7181,2243,819*13,874(19,996)
Interest income2,7332,905*2,6762,7633,1422,738*723619578495*437595
Interest expense43145*525149129*41125949123*2400
Other income (expense)234(368)*(186)(349)(86)(390)*7561,73941(14)*1,394501
Income tax expense (benefit)9,1849,845*10,5749,7718,0015,945*7,4498,3738,4565,772*8,5069,051
Net income (loss)11,34716,766*16,53710,43210,6074,454*9,4029,655(6,522)(1,775)*7,515(21,382)
Earnings per share, basic USD per share0.590.88*0.860.550.560.23*0.490.52(0.36)(0.10)*0.41(1.16)
Earnings per share, diluted USD per share0.590.87*0.860.540.560.23*0.490.52(0.36)(0.10)*0.41(1.16)
Weighted average shares, basic thousands of shares19,24519,151*19,17419,07319,07819,087*19,04918,51318,29318,303*18,39818,486
Weighted average shares, diluted thousands of shares19,37219,253*19,30219,15919,08319,104*19,08518,53618,29318,396*18,41118,486

Balance sheet

CSV

Fiscal quarters (USNA's year ends in early January)

In thousands of dollarsSep 30, 2023Dec 30, 2023Mar 30, 2024Jun 29, 2024Sep 28, 2024Dec 28, 2024Mar 29, 2025Jun 28, 2025Sep 27, 2025Jan 3, 2026Apr 4, 2026Jul 4, 2026
Cash and cash equivalents307,081330,420328,336332,423364,889181,768179,613151,338145,349158,380162,751168,560
Inventory60,08161,45460,87061,83263,98469,73573,55783,26990,781102,60896,35886,343
Prepaid and other current assets23,29825,87231,86424,82622,31827,68428,22427,25927,93527,41725,46722,826
Total current assets390,460417,746421,070419,081451,191279,187281,394261,866264,065288,405294,233281,066
Property and equipment, net95,15999,81498,18697,68698,03394,56594,24596,53296,21294,38394,62594,269
Right-of-use asset—17,671———21,177———22,954——
Goodwill16,80117,10216,90216,83717,196144,168144,218144,230144,288137,962138,127109,141
Total assets601,148632,757629,275631,419671,308748,193746,596734,526726,591742,915738,966703,210
Accounts payable9,32110,0708,2666,6487,04111,98413,97417,89916,21917,26316,23015,431
Accrued liabilities—9,750———13,569———9,500——
Total current liabilities112,559118,845112,631103,896114,779139,625137,383121,625118,664128,565117,239105,675
Lease liability, non-current—5,141———10,191———12,306——
Total liabilities—135,555———161,861162,723148,968145,038156,643144,180132,237
Retained earnings428,447445,217453,451463,883474,490478,944477,628474,017467,495465,720473,235451,853
Total stockholders' equity470,394497,202499,988512,208533,087532,109529,762531,060528,074533,104543,550526,306
Total liabilities and equity601,148632,757629,275631,419671,308748,193746,596734,526726,591742,915738,966703,210
Common shares outstanding (cover page) thousands of shares19,13019,24119,05119,05219,06018,90518,62318,27218,28118,45718,46318,477

Cash flows

CSV

Fiscal quarters (USNA's year ends in early January)

In thousands of dollarsSep 30, 2023Dec 30, 2023Mar 30, 2024Jun 29, 2024Sep 28, 2024Dec 28, 2024Mar 29, 2025Jun 28, 2025Sep 27, 2025Jan 3, 2026Apr 4, 2026Jul 4, 2026
Net income (loss)11,34716,766*16,53710,43210,6074,454*9,4029,655(6,522)(1,775)*7,515(21,382)
Stock-based compensation3,670*3,643*3,6693,734*3,542*3,613*2,8803,622*3,576*3,750*3,4543,404*
Depreciation and amortization3,271*2,912*3,1583,8133,5693,999*8,3397,7437,9198,561*8,2777,674
Net cash from operating activities22,234*26,023*17,6837,990*29,534*5,785*15,48212,218*(1,961)*(3,390)*9,75923,319*
Purchases of property and equipment1,454*7,324*3,2012,671*2,399*1,802*2,8035,027*3,198*2,795*2,6453,155*
Net cash from investing activities(1,454)*(7,322)*(4,068)(1,546)*(2,338)*(205,138)*(3,875)(4,162)*(3,198)*1,110*(2,597)(4,057)*
Share repurchases11,599*0*9,4440*0*0*12,30015,207*0*0*00*
Net cash from financing activities(11,641)*658*(11,946)(1,353)*(78)*22,930*(14,467)(38,610)*(979)*13,453*(3,641)(14,026)*
Net change in cash6,882*23,423*(2,140)4,069*32,566*(183,233)*(2,141)(28,241)*(5,973)*13,087*4,4175,851*

Compare with peers

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Usana Health Sciences168,560223,27323,319*18.5M— 10-QJul 4, 2026
Altimmune63,008not reported(24,221)*194.5M13.5 quarters 10-QJun 30, 2026
Prothena Corp Public288,1931,010(25,049)*51.3M11.5 quarters 10-QJun 30, 2026
Rigel Pharmaceuticals60,81678,70330,653*18.7M— 10-QJun 30, 2026
Amarin156,51239,5509,223*not reported— 10-QSep 30, 2026
Aura Biosciences67,836not reported(32,501)*103.7M2.1 quarters 10-QJun 30, 2026
Nektar Therapeutics39,26710,131(75,770)*34.1M9.0 quarters 10-QJun 30, 2026
Northwest Biotherapeutics595807(7,169)*1.7B0.1 quarters 10-QJun 30, 2026
Emergent BioSolutions175,700110,000100,100*51.4M— 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.